Thursday, August 06, 2015

Just Good Business Practice

Pharmaceutical firms Pfizer and Flynn Pharma have been accused by the Competition and Markets Authority, the UK's competition watchdog of charging "excessive and unfair" prices for an anti-epilepsy drug. Phenytoin sodium capsules, used by 50,000 people in Britain, are made by Pfizer and sold by Flynn.

When Pfizer made the drug under its Epanutin brand name, the NHS spent about £2.3m on the drug, the CMA said. This amount soared to £50m in 2013. The CMA said Pfizer sold UK distribution rights to Flynn in 2012, but continued to make and supply the drug to the company. It was after this deal that prices rose. 

No comments: